Corcept Therapeutics Incorporated

CORT.US
Healthcare · Biotechnology
94.19
+3.07 (+3.37%)
USD · NASDAQ

Company Information

Company Name
Corcept Therapeutics Incorporated
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
ISIN: US2183521028
CIK: 0001088856
CUSIP: 218352102
Currency: USD
Full Time Employees: 730
Phone: 650 327 3270
Fiscal Year End: December
IPO Date: Apr 14, 2004
Description:

Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. It also develops relacorilant, a selective cortisol modulator for patients with hypercortisolism; a selective cortisol modulator miricorilant, which is in Phase 1b trial for metabolic dysfunction-associated steatohepatitis; and a portfolio of proprietary selective cortisol modulators, such as relacorilant, nenocorilant, miricorilant, and dazucorilant for the treatment of Lou Gehrig's disease. The company was incorporated in 1998 and is headquartered in Redwood City, California.

Address:

101 Redwood Shores Parkway, Redwood City, CA, United States, 94065

People

Directors & Officers

Name Title Year Born
Dr. Joseph K. Belanoff M.D. Co-Founder, President, CEO & Director 1957
Mr. Atabak Mokari CFO & Treasurer 1977
Mr. Sean Maduck President of Endocrinology 1977
Dr. William Guyer Pharm.D. Chief Development Officer 1968
Mr. Gary Charles Robb J.D. Chief Business Officer & Secretary 1963
Mr. Joseph Douglas Lyon Chief Technology & Accounting Officer 1978
Dr. Hazel Hunt Ph.D. Chief Scientific Officer 1960
Ms. Amy Flood Chief Human Resources & Communications Officer NA
Ms. Monica Tellado President of Emerging Markets 1973
Mr. Roberto W. Vieira President of Oncology NA

Insider Trading

Date Insider Name Title Transaction Type Shares Price Value
Apr 07, 2026 William Guyer N/A Sale 20.00K $40.97 $819.40K
Mar 25, 2026 Joseph K Belanoff N/A Sale 26.20K $50.07 $1.31M
Mar 20, 2026 William Guyer N/A Sale 11.77K $36.01 $423.73K
Mar 17, 2026 G Leonard Baker Jr N/A Purchase 100.00K $33.14 $3.31M
Mar 04, 2026 William Guyer N/A Sale 8.23K $35.99 $296.31K
Feb 03, 2026 William Guyer N/A Sale 20.00K $40.87 $817.40K
Jan 06, 2026 William Guyer N/A Sale 20.00K $35.18 $703.60K
Dec 02, 2025 William Guyer N/A Sale 20.00K $80.08 $1.60M
Dec 01, 2025 Sean Maduck N/A Sale 20.00K $79.52 $1.59M
Dec 01, 2025 Joseph K Belanoff N/A Sale 40.00K $79.77 $3.19M
Dec 01, 2025 Joseph Douglas Lyon N/A Sale 5.00K $79.53 $397.65K
Nov 25, 2025 William Guyer N/A Sale 4.50K $80.90 $364.05K
Nov 05, 2025 Joseph K Belanoff N/A Sale 28.78K $74.77 $2.15M
Nov 05, 2025 William Guyer N/A Sale 20.00K $75.36 $1.51M
Nov 03, 2025 Sean Maduck N/A Sale 20.00K $73.99 $1.48M
Nov 03, 2025 Joseph K Belanoff N/A Sale 11.22K $74.08 $831.03K
Nov 03, 2025 Joseph Douglas Lyon N/A Sale 5.00K $73.65 $368.25K
Oct 10, 2025 Daniel N Swisher Jr N/A Sale 2.20K $87.54 $192.59K
Oct 07, 2025 William Guyer N/A Sale 20.00K $89.94 $1.80M
Oct 01, 2025 Joseph Douglas Lyon N/A Sale 5.00K $84.75 $423.75K

Shareholders

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
BlackRock Inc 12.15M Mar 31, 2026 11.32% $0.01 0.74%
Vanguard Group Inc 9.49M Dec 31, 2025 8.84% $0.00 -0.44%
Ingalls & Snyder LLC 7.61M Mar 31, 2026 7.09% $10.86 5.75%
Renaissance Technologies Corp 5.68M Mar 31, 2026 5.29% $0.36 -1.32%
Vanguard Portfolio Management, LLC 4.82M Mar 31, 2026 4.49% $0.01 0.00%
Vanguard Capital Management, LLC 4.08M Mar 31, 2026 3.80% $0.00 0.00%
Parallel Advisors, LLC 3.98M Mar 31, 2026 3.71% $2.88 2.53%
State Street Corp 3.20M Mar 31, 2026 2.98% $0.00 7.20%
FMR Inc 3.19M Mar 31, 2026 2.97% $0.01 32.12%
Geode Capital Management, LLC 2.71M Mar 31, 2026 2.53% $0.01 1.67%
First Trust Advisors L.P. 2.17M Mar 31, 2026 2.02% $0.06 213.48%
Dimensional Fund Advisors, Inc. 1.55M Mar 31, 2026 1.45% $0.01 -4.15%
TANG CAPITAL MANAGEMENT LLC 1.50M Mar 31, 2026 1.40% $3.07 856.85%
UBS Group AG 1.36M Mar 31, 2026 1.27% $0.01 228.71%
D. E. Shaw & Co LP 1.18M Mar 31, 2026 1.10% $0.03 596.27%
Charles Schwab Investment Management Inc 1.12M Mar 31, 2026 1.04% $0.01 5.45%
Morgan Stanley - Brokerage Accounts 1.02M Mar 31, 2026 0.95% $0.00 -36.00%
MPM Oncology Impact Management LP 985.70K Mar 31, 2026 0.92% $3.07 0.00%
Two Sigma Investments LLC 945.88K Mar 31, 2026 0.88% $0.03 3,283.11%
HPM Partners LLC 731.69K Mar 31, 2026 0.68% $0.04 -3.13%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 iShares Core S&P Small-Cap ETF 5.75M 5.36% ▲ 0.01% Jun 30, 2026
2 Vanguard Total Stock Mkt Idx Inv 2.89M 2.70% ▲ 0.39% Jun 30, 2026
3 Vanguard Small Cap Index 2.09M 1.95% ▲ 0.60% Jun 30, 2026
4 First Trust NYSE Arca Biotech ETF 1.81M 1.69% ▼ 1.73% Jun 30, 2026
5 Vanguard Small Cap Growth Index Inv 1.21M 1.13% ▲ 3.32% Jun 30, 2026
6 Fidelity Contrafund 1.19M 1.11% ▲ 0.00% May 31, 2026
7 Vanguard Institutional Extnd Mkt Idx Tr 1.10M 1.02% ▲ 3.56% Jun 30, 2026
8 State Street SPDR Port S&P 600 Sm CpETF 876.53K 0.82% ▼ 0.49% Jun 30, 2026
9 iShares S&P Small-Cap 600 Growth ETF 861.38K 0.80% ▲ 0.33% Jun 30, 2026
10 Vanguard Tax-Managed Small Cap Adm 615.79K 0.57% ▲ 0.00% Jun 30, 2026

Financial Highlights

Market Cap: $10.11B
EBITDA: $-6.94M
P/E Ratio: $261.64
PEG Ratio: $0.81
Book Value: $5.94
Earnings/Share: $0.36
Profit Margin: 6.16%
Operating Margin: -30.08%
ROA (TTM): -0.62%
ROE (TTM): 7.17%
Revenue (TTM): $769.10M
Revenue/Share (TTM): $7.40
Earnings Growth (YOY): -21.60%
Revenue Growth (YOY): 4.90%

Valuation Metrics

Enterprise Value: $9.45B
Trailing P/E: 261.64
Forward P/E: 112.36

Shares Statistics

Shares Outstanding: 107.35M
Shares Float: 89.94M
% Insiders: 1,154.00%
% Institutions: 7,554.00%
Short % Float: 11.36%

Stock Price History

1 Year Price History

2 Years Price History

5 Years Price History

10 Years Price History

Financial Charts

Revenue & Net Income (Yearly)

Revenue & Net Income (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

Open full waterfall
Line Item
Step Type
Value
Revenue
adjust
$761.41M
Cost of Goods Sold
adjust
$-12.98M
Gross Profit
subtotal
$748.43M
SG&A
adjust
$-448.73M
R&D
adjust
$-254.91M
Operating Income
subtotal
$44.80M
Other / Non-Operating Items
adjust
$54.86M
Net Income
subtotal
$99.65M

Earnings Per Share (EPS) History

Financial Ratios

📦 Raw API Data (JSON Explorer)

Watchlist

0

No stocks in watchlist

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about CORT.US!